Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedra is back

This article was originally published in The Tan Sheet

Executive Summary

American Generics Laboratories has launched four new ephedra-containing weight-loss supplements "as a result of high consumer demand following the recent overturning of the 2004 FDA ban on ephedra-based products," according to an announcement Nov. 16. The Salt Lake City, Utah-based firm was founded in August and is marketing Superdrine RX-10, Ripped Power, Metabothin and Super Ephedra Extreme online for $39.99 - $59.99. "The products are manufactured in FDA-approved facilities and are of daily dosages permitted by law," the firm maintains. FDA banned dietary supplements containing ephedrine alkaloids in 2004. However, a Utah District Court overturned the ban in April for Nutraceutical Corporation's 10 mg product. FDA is appealing the court's decision (1"The Tan Sheet" Nov. 14, 2005, p. 4)...
Advertisement

Related Content

“No Evidence” Exists That Ephedra Ban Shifted Burden Of Proof, Agency Says
“No Evidence” Exists That Ephedra Ban Shifted Burden Of Proof, Agency Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS098868

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel